CA2317093A1 - Agonistes de recepteur d'adenosine a2a - Google Patents

Agonistes de recepteur d'adenosine a2a Download PDF

Info

Publication number
CA2317093A1
CA2317093A1 CA002317093A CA2317093A CA2317093A1 CA 2317093 A1 CA2317093 A1 CA 2317093A1 CA 002317093 A CA002317093 A CA 002317093A CA 2317093 A CA2317093 A CA 2317093A CA 2317093 A1 CA2317093 A1 CA 2317093A1
Authority
CA
Canada
Prior art keywords
alkyl
disease
groups
wrc
amino groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002317093A
Other languages
English (en)
Inventor
Joel M. Linden
W. Michael Sheld
Ian Sarembock
Gail W. Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia Patent Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2317093A1 publication Critical patent/CA2317093A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des agonistes de récepteurs d'adénosine A¿2A? combinés avec du rolipram, leurs dérivés ou d'autres inhibiteurs de phosphodiestérase (PDE) type IV qui sont efficaces pour le traitement de maladies inflammatoires.
CA002317093A 1998-01-08 1999-01-07 Agonistes de recepteur d'adenosine a2a Abandoned CA2317093A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US393098A 1998-01-08 1998-01-08
US09/003,930 1998-01-08
PCT/US1999/000366 WO1999034804A1 (fr) 1998-01-08 1999-01-07 Agonistes de recepteur d'adenosine a¿2a?

Publications (1)

Publication Number Publication Date
CA2317093A1 true CA2317093A1 (fr) 1999-07-15

Family

ID=21708282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002317093A Abandoned CA2317093A1 (fr) 1998-01-08 1999-01-07 Agonistes de recepteur d'adenosine a2a

Country Status (5)

Country Link
EP (1) EP1044004A1 (fr)
JP (1) JP2002500188A (fr)
AU (1) AU2108299A (fr)
CA (1) CA2317093A1 (fr)
WO (1) WO1999034804A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
WO1998057651A1 (fr) 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions et procedes prevenant les restenoses consecutives a des interventions de revascularisation
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
WO2000072799A2 (fr) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Methode et compositions permettant de traiter la reponse inflammatoire
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1278748B1 (fr) * 2000-04-25 2011-03-23 ICOS Corporation Inhibiteurs de la phosphatidyl-inositol 3-kinase delta humaine
WO2001093909A2 (fr) * 2000-06-06 2001-12-13 Glaxo Group Limited Procede de traitement du cancer
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
AU2003234716A1 (en) * 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
EP1761540B1 (fr) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
WO2006028618A1 (fr) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
EP2266994B1 (fr) 2004-08-02 2013-04-03 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste A2A
MX2007003271A (es) 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
WO2007107598A1 (fr) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Agonistes du récepteur a2a phosphorylé
EP2178370A4 (fr) * 2007-07-17 2011-01-12 Zalicus Inc Combinaisons pour le traitement des troubles prolifératifs des lymphocytes b
CA3092449A1 (fr) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies pour tumeurs malignes hematologiques
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
MX2011009955A (es) 2009-03-24 2011-11-18 Gilead Calistoga Llc Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
AU2013203620B2 (en) 2012-03-05 2015-11-19 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
PL3083630T3 (pl) 2013-12-20 2020-02-28 Gilead Calistoga Llc Sposoby otrzymywania inhibitorów 3-kinazy fosfatydyloinozytolu
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
WO1999034804A1 (fr) 1999-07-15
EP1044004A1 (fr) 2000-10-18
JP2002500188A (ja) 2002-01-08
AU2108299A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
CA2317093A1 (fr) Agonistes de recepteur d'adenosine a2a
US6448235B1 (en) Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) Method compositions for treating the inflammatory response
US6670334B2 (en) Method and compositions for treating the inflammatory response
US5877180A (en) Method for treating inflammatory diseases with A2a adenosine receptor agonists
WO2000072799A2 (fr) Methode et compositions permettant de traiter la reponse inflammatoire
JP4980530B2 (ja) アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物
EP3406260B1 (fr) Inhibiteurs de kinases dépendant de la cycline et leurs procédés d'utilisation
US6579857B1 (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
KR20140064765A (ko) Hcv 조합 치료
AU2004216891B2 (en) Use of adenosine receptor agonists in therapy
US20080161248A1 (en) Methods and Compositions for Therapeutic Treatment
de la Rubia et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study
EP1272897A2 (fr) Antagonistes des recepteurs d'adenosine a2a pour le traitement et la prevention de la cirrhose hepatique et de la steatose hepatique
US20230263800A1 (en) Compositions and methods to promote thymic function
US6103702A (en) Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
Kandzari et al. MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury
List et al. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients
US20220257629A1 (en) Compositions and methods for upregulation of human fetal hemoglobin
CN116940365A (zh) 慢性髓性白血病干细胞抑制剂
Miura et al. Ischemic preconditioning against infarction: Its mechanism and clinical implications
JP2020504163A (ja) 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物

Legal Events

Date Code Title Description
FZDE Dead